AVEO_LG Chem_Logo(Hi-Resolution).jpg
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
February 06, 2024 08:10 ET | AVEO Pharmaceuticals, Inc.
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib
Logo.jpg
FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma
July 31, 2023 06:00 ET | Invectys, Inc.
Houston, TX, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the...
Vaccentis CMO
Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development
May 03, 2023 03:00 ET | Vaccentis AG
Zurich, Switzerland, May 3, 2023 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life...
Mario Stark
Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer
September 08, 2022 02:00 ET | Vaccentis AG
Life science executive with experience in ophthalmology, branding, marketing and financingWill lead sales and marketing of medicines for dry eye and autoimmune diseases Zurich, Switzerland,...
_76A4572
Vaccentis appoints Martin Munte as CEO and strengthens Board
July 12, 2022 02:00 ET | Vaccentis AG
Martin Munte has extensive leadership experience at Amgen, AstraZeneca and RocheStrengthening management after appointment of three new Board members Zurich, Switzerland, July 12, 2022 -...
_76A4572
Vaccentis stärkt Management durch Berufung von Martin Munte zum CEO
July 12, 2022 02:00 ET | Vaccentis AG
Pharmamanager mit langjährige Führungserfahrung bei Amgen, AstraZeneca und RocheWeitere Verstärkung des Managements nach Ernennung dreier neuer Mitglieder im Verwaltungsrat Zurich, Schweiz, 12....
logo.png
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
December 22, 2021 08:00 ET | Allarity Therapeutics, Inc.
Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs NDA is supported by Allarity’s previously-filed pre-market approval (PMA)...
DareBio_Stacked_Fullcolor_RGB.jpg
Cerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results
November 13, 2014 16:06 ET | Daré Bioscience, Inc.
CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today provided an update on corporate activities during the quarter...
DareBio_Stacked_Fullcolor_RGB.jpg
Cerulean Appoints Vice President, Regulatory Affairs
October 06, 2014 09:02 ET | Daré Bioscience, Inc.
CAMBRIDGE, Mass., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of Pamela Strode as Vice President,...